Displaying 1181 - 1200 of 1541
Contact Lens Rule
New Mexico Physicians' Group Agrees to Settle FTC Price-Fixing Charges
Jackson, Tennessee Hospital Co. v. West Tennessee Healthcare, Inc
Announced Actions for May 25, 2004
Bristol-Myers Squibb Company, In the Matter of
Bristol-Myers Squibb Company (BMS) settled charges that it engaged in illegal business practices to delay the entry of three low price generic pharmaceuticals that would be in direct competition with three of its branded drugs. The complaint alleged that BMS purposely made wrongful listings in the Orange Book of the U.S. Food & Drug Administration and that it also paid a potential competitor over $70 million to delay the entry of its generic drug. The three drugs involved in the complaint are: Taxol (containing the active ingredient paclitaxel) – used to treat ovarian, breast, and lung cancers; Platinol (containing the active ingredient cisplatin) – used for the treatment of various forms of cancer; and BuSpar (containing the active ingredient buspirone) – used to manage anxiety disorders. To prevent recurrence of Bristol's pattern of alleged improper listings, the consent order eliminates Bristol's ability to obtain a 30-month stay on later-listed patents. By denying Bristol the benefit of the 30-month stay on later-listed patents, the order would reduce Bristol's incentive to engage in improper behavior before the PTO and the FDA to obtain and list a patent for the purpose of obtaining an unwarranted automatic 30-month stay.
Announced Action for May 11, 2004
Health Care Information and Competition conference
FTC Staff: Rhode Island Bills Would Raise Prices for Pharmaceuticals
Eyeglass Rule
Announced Actions for April 2, 2004
Teva Pharmaceuticals USA, Inc. v. Pfizer, Inc.
FTC Closes Its Investigation Into Caremark Rxs Proposed Acquisition of Advance PCS
FTC Challenges Hospital Merger That Allegedly Led to Anticompetitive Price Increases
San Franciscos Brown & Toland Medical Group Settles FTC Price Fixing Charges
Tenet Healthcare Corporation and Frye Regional Medical Center, Inc.
A consent order prohibits Frye Regional Medical Center, Inc., an acute care hospital in Hickory, North Carolina, and its parent company Tenet Healthcare Corporation from entering into any agreement to negotiate fees on behalf of any physician practicing in four North Carolina counties and from refusing to deal with insurance companies and other payers. Also refer to related administrative complaint issued to Piedmont Health Alliance. This settlement is the first case in which the Commission has named a hospital as a participant in an alleged physician price-fixing conspiracy.
Diagnosing Physician-Hospital Organizations
FTC Closes its Investigation of Genzyme Corporation's 2001 Acquisition of Novazyme Pharmaceuticals, Inc.
Displaying 1181 - 1200 of 1541